BPG is committed to discovery and dissemination of knowledge
Observational Study
Copyright: ©Author(s) 2026.
World J Gastroenterol. Apr 28, 2026; 32(16): 116405
Published online Apr 28, 2026. doi: 10.3748/wjg.v32.i16.116405
Table 2 Comparison of baseline characteristics in the matched cohort (n = 220), n (%)
Characteristic
n
Ultra-low group (≤ 3 cm; n = 110)
Non-ultra-low group (> 3 cm; n = 110)
Test statistic
P value
Age (year)22058.08 ± 10.97864.47 ± 11.242t = 4.2660.576
Gender
    Female9541 (37.3)54 (49.1)χ2 = 3.1310.077
    Male12569 (62.7)56 (50.9)
BMI (kg/m2)23.75 ± 3.1423.23 ± 2.99t = -1.2590.933
Blood type
    A7437 (33.6)37 (33.6)χ2 = 1.5300.675
    AB1610 (9.1)6 (5.5)
    B5026 (23.6)24 (21.8)
    O8037 (33.6)43 (39.1)
Diabetes
    No17691 (82.7)85 (77.3)χ2 = 1.0230.312
    Yes4419 (17.3)25 (22.7)
Hypertension
    No15076 (69.1)74 (67.3)χ2 = 0.0840.772
    Yes7034 (30.9)36 (32.7)
Tumor pathology
    Adenocarcinoma20297 (88.2)105 (95.5)χ2 = 4.5830.205
    Mucinous adenocarcinoma1511 (10.0)4 (3.6)
    Neuroendocrine carcinoma11 (0.9)0 (0.0)
    Signet ring cell carcinoma21 (0.9)1 (0.9)
TNM
    02713 (11.8)14 (12.7)χ2 = 25.940< 0.001
    I8232 (29.1)50 (45.5)
    II5722 (20.0)35 (31.8)
    III3326 (23.6)7 (6.4)
    IV2117 (15.5)4 (3.6)
Postoperative complications
    No210106 (96.4)104 (94.5)χ2 = 0.4190.517
    Yes104 (3.6)6 (5.5)
Neoadjuvant radiotherapy
    No13646 (41.8)90 (81.8)χ2 = 37.283< 0.001
    Yes8464 (58.2)20 (18.2)
Neoadjuvant chemotherapy
    No10226 (23.6)76 (69.1)χ2 = 45.696< 0.001
    Yes11884 (76.4)34 (30.9)


Write to the Help Desk